With an ever-increasing project demand from our clients in Japan, and as part of our Asia expansion plan, we are delighted to announce the opening of our new Tokyo office. Pharmaspectra has been working with Japan-based clients for 15 years, providing the most comprehensive coverage of local science available through our world-leading data lake. Having a dedicated team in the country will enable us to better serve our clients and local market needs in an even more targeted and effective way.
Pharmaspectra captures all science as it is disseminated the world over and we are committed to supporting our customers in the fight against the COVID-19 pandemic. With this purpose in mind, we have built a database specifically for coronaviruses, that is tracking information containing all publications and meeting proceedings in real time, as soon as the science becomes available.
With medical literature, it’s not only important to access the information from the tens of thousands of global sources, but to understand the historical context as well.
Pharmaspectra receives funding from private equity firm, Inflexion.
The rise of these predatory journals has largely been driven by the “publish or perish” dictum predominant in academia, where careers, promotions, and funding can depend on publishing research. To identify these problematic publications, look for these hallmarks
Where to Publish Drug Trial Results? Traditional Journal Rankings Fail to Deliver their Promised Impact